POROCARCINOMA

Clinical trials for POROCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new POROCARCINOMA trials appear

Sign up with your email to follow new studies for POROCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors

Disease control Ongoing

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

Matched conditions: POROCARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Aug 15, 2026 00:00 UTC

POROCARCINOMA

Get alerted when new POROCARCINOMA trials appear

Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors